Hematological Oncology
Hematological Oncology is a journal indexed in SJR in Medicine (miscellaneous) and Hematology with an H index of 57. It has a price of 3333 €. It has an SJR impact factor of 1,027 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,027.
Metrics
Scimago and CountryOfPapers database fields
SJR Impact
1,027
H-index
57
Docs (year)
100
Docs 3y
369
Total refs
3526
Cites 3y
877
Citable 3y
289
Cites/Doc 2y
2.43
Ref/Doc
35.26
Immediate OA
3333 €
Embargoed OA
NPD
Non OA / Submission
0 €
Name good journals. Call out predatory ones.
Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.
Researcher reviews
Best articles by citations
Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma
View moreXI. How to treat children and adolescents with relapsed non-Hodgkin lymphoma?
View moreCurrent Awareness in Hematological Oncology
View moreCurrent and future use of hematopoietic growth factors in cancer medicine
View moreCover Image
View moreCore needle biopsy as a front line diagnostic approach for lymphoma patients
View moreConventional and high-dose daunorubicin and idarubicin in acute myeloid leukaemia remission induction treatment: a mixed treatment comparison meta-analysis of 7258 patients
View moreComparison of the performance of anti-CD7 and anti-CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T-cell acute lymphoblastic leukemia cell line
View moreComparison of fixed dose pegfilgrastim and daily filgrastim after autologous stem cell transplantation in patients with multiple myeloma autografted on a outpatient basis
View moreClinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era
View moreCladribine-based salvage regimen-induced deep remission of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in leukemia phase
View moreCharacteristics and survival of patients with non-Hodgkin's lymphoma with and without acquired immunodeficiency syndrome
View moreCandidate gene association studies and risk of Hodgkin lymphoma: a systematic review and meta-analysis
View moreA review of the trends of lymphomas in the equatorial belt of Africa
View moreBone mineral density (BMD) in patients with lymphoma: The effects of chemotherapy, intermittent corticosteroids and premature menopause
View moreBone marrow donation perceptions among healthcare workers: a survey at University of Toledo Medical Center
View moreBlood and lymph vessels in embryonic tumors
View moreBLOCKADE OF THE PD-1 CHECKPOINT WITH ANTI-PD-L1 ANTIBODY AVELUMAB IS SUFFICIENT FOR CLINICAL ACTIVITY IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL)
View moreAXICABTAGENE CILOLEUCEL (AXI-CEL; KTE-C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON-HODGKIN LYMPHOMAS (NHL): PRIMARY RESULTS OF THE PIVOTAL TRIAL ZUMA-1
View moreAssociation betweenHelicobacter pylori infection and MALT-type lymphoma of the ocular adnexa: clinical and therapeutic implications
View moreAntileukaemia effect of rapamycin alone or in combination with daunorubicin on ph+ acute lymphoblastic leukaemia cell line
View moreAntibiotic prophylaxis in chemotherapy-induced neutropenia: time to reconsider
View moreAnalysis of the prognostic value of BMI and the difference in its impact according to age and sex in DLBCL patients
View moreAcute myeloid leukemia with concurrent myeloid sarcoma treated with autologous bone marrow transplantation: two illustrative cases and a literature review
View more